Foghorn Therapeutics Inc.
For the period ended Oct 30, 2025. Filed Oct 30, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Oct 30, 2025 · Filed Oct 30, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.2 · Selective EP300 Degrader Program
Selective EP300 Degrader Program
EP300 is an acetyltransferase that is implicated in hematological malignancies such as multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL), and prostate cancer. Attempts to selectively drug EP300 have been challenging due to the high level of similarity with CBP, and dose-limiting toxicities associated with dual inhibition of both CBP and EP300.
Foghorn is advancing a Selective EP300 degrader program, with an initial focus in MM and DLBCL, on track for IND-enabling studies in 2026. Key updates include:
Broad anti-tumor activity in over 70% of all heme sub-lineages tested
VHL based selective degrader shows efficacy in MM without hematological toxicities, including thrombocytopenia
EP300 degraders show efficacy in IMiD-resistant MM cell lines
Tolerability profile with widespread potential for combinations
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.